Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal and age-related interstitial lung disease whose etiology and pathogenesis are still largely unknown. It is important to identify IPF patients at high risk of mortality so that early appropriate treatment can improve their prognosis. Therefore, the investigation of available and reliable prognostic biomarkers for IPF is crucial.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Current status and future prospects
Cell and gene therapies in modern cardiology
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people
Benefit of the high-dose influenza vaccine
- Findings from the ALS Symposium 2024 in Montreal